StockMarketWire.com - AstraZeneca and Merck said their ovarian cancer drug combined with bevacizumab had improved survival rates, meeting its primary goal during clinical trials.

Women who took Lynparza plus bevacizumab lived longer without disease progression or death versus those taking bevacizumab alone, the company said.

'The positive results from the PAOLA-1 trial demonstrate a clear potential benefit of adding Lynparza to the standard-treatment bevacizumab for women with advanced ovarian cancer,' said JoseĢ Baselga, Executive Vice President, Oncology R&D.

'Following positive results from the SOLO-1 trial for women with a BRCA gene mutation, the PAOLA-1 trial marks yet another positive Phase III trial for Lynparza as a 1st-line maintenance treatment for women with advanced ovarian cancer. We look forward to discussing the results with global health authorities as soon as possible.'



Story provided by StockMarketWire.com